SOAT1 and myeloproliferative neoplasm: The identification of the specific dependence of MPN on JAK/STAT pathway dysregulation, irrespective of the underlying driver mutation, led to the development of small-molecule inhibitors of the JAK family of tyrosine kinases (JAKi).